Tate & Lyle (TATE) H1 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 TU earnings summary
17 Dec, 2025Executive summary
Strong progress in integrating CP Kelco, with the cross-selling pipeline value more than doubling in the last two months and strong customer engagement.
Customers recognize the strength of the combined portfolio, especially in mouthfeel and reformulation expertise.
Actions are being accelerated to drive top-line growth, including enhanced customer segmentation, strengthened customer-facing capabilities, and optimized manufacturing capacity.
Despite integration benefits, recent months saw a slowdown in demand, particularly in North America, amid considerable economic volatility.
Fundamental growth drivers remain strong, particularly in healthier and more nutritious food and drink.
Financial highlights
Group revenue for H1 expected to be 3%-4% lower year-over-year in constant currency, compared to pro forma comparatives.
EBITDA for H1 anticipated to be high single-digit percent lower, reflecting top-line softness and ongoing investments.
For the full year ending March 2026, revenue and EBITDA are expected to decline by low single-digit percent year-over-year in constant currency.
In the Americas, H1 revenue is expected to be slightly lower due to softer consumer demand.
In EMEA, revenue is expected to be mid-single digit lower, while Asia Pacific revenue is expected to be broadly in line after absorbing tariffs.
Outlook and guidance
Near-term market demand expected to remain challenging, with improvement anticipated in Q4 due to integration benefits and cost synergies.
No assumption of near-term market recovery; Q4 improvement expected from internal actions and combination benefits.
Full-year guidance assumes continued tariff impacts and conservative pricing assumptions.
Improvement will be driven by accelerated top-line growth actions and increasing benefits from the CP Kelco combination.
Latest events from Tate & Lyle
- Q3 revenue rose 15% reported, but pro forma revenue fell 2%; outlook remains unchanged.TATE
Q3 2026 TU2 Mar 2026 - $1.8B deal creates a global specialty food leader with strong synergies and growth prospects.TATE
Business Combination (Q&A)3 Feb 2026 - A $1.8B deal creates a global specialty food leader, targeting strong cost and revenue synergies.TATE
Business Combination3 Feb 2026 - EBITDA up 6% and margin expands as specialty strategy advances with CP Kelco and Primient sale.TATE
H1 202516 Jan 2026 - EBITDA up 6%, cash flow strong, and strategic transformation completed.TATE
H1 2025 (Q&A)16 Jan 2026 - Volume and EBITDA growth, CP Kelco integration, and strong cash generation support future synergies.TATE
Trading Update17 Dec 2025 - Transformed into a high-margin specialty leader, targeting accelerated growth and innovation.TATE
CMD 202521 Nov 2025 - Specialty focus and CP Kelco integration drive EBITDA and cash flow growth amid tariff risks.TATE
H2 202519 Nov 2025 - Revenue and EBITDA declined 3% and 6%, but CP Kelco synergies and growth actions advance.TATE
H1 202613 Nov 2025